Literature DB >> 7853434

Double-blind comparison of oral gentamicin and nalidixic acid in the treatment of acute shigellosis in children.

M R Islam1, A N Alam, M S Hossain, D Mahalanabis, H K Hye.   

Abstract

To compare the efficacy of oral gentamicin with nalidixic acid in the treatment of acute shigellosis, we studied, in a double blind-trial, 79 comparable children with bloody diarrhoea of less than 72 h duration. Of them Shigella spp. were isolated in 71 patients. Patients were randomly assigned to receive either gentamicin 30 mg/kg/day or nalidixic acid 60 mg/kg/day, both given orally in four equal doses for 5 days. Stool frequency differed significantly between the groups from day two until completion of the study. Treatment failure was observed in 14 (42 per cent) patients receiving oral gentamicin compared to none of those with nalidixic acid-sensitive strains of Shigella spp. (P = 0.0002). Although all the shigella isolates were sensitive to gentamicin in vitro, 19 (58 per cent) patients on gentamicin therapy failed to eliminate shigella organisms from stool, compared to none in the nalidixic acid treated group infected with nalidixic acid-sensitive Shigella spp. (P < 0.001). One patient in each group had a bacteriological relapse. We conclude that gentamicin given orally was therapeutically ineffective in the treatment of acute shigellosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7853434     DOI: 10.1093/tropej/40.6.320

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN: 0142-6338            Impact factor:   1.165


  3 in total

Review 1.  Antibiotic therapy for Shigella dysentery.

Authors:  Prince Rh Christopher; Kirubah V David; Sushil M John; Venkatesan Sankarapandian
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

Review 2.  Identification and management of Shigella infection in children with diarrhoea: a systematic review and meta-analysis.

Authors:  Kirkby D Tickell; Rebecca L Brander; Hannah E Atlas; Jeffrey M Pernica; Judd L Walson; Patricia B Pavlinac
Journal:  Lancet Glob Health       Date:  2017-12       Impact factor: 38.927

3.  Evaluation of in vitro and in vivo antibiotic efficacy against a novel bioluminescent Shigella flexneri.

Authors:  Molly C McCloskey; Shareef Shaheen; Lesley Rabago; Matthew A Hulverson; Ryan Choi; Lynn K Barrett; Samuel L M Arnold
Journal:  Sci Rep       Date:  2019-09-19       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.